Conclusions: This study underscores the role of RhoA in LSC behavior under TKI treatment and suggests that SKF-96365 could remobilize quiescent CML LSCs through reactivation of the RhoA/ROCK pathway. Here, RHOA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.